GB:CURE
VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD
$26.93
VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD (GB:CURE) Price & Chart
GB:CURE ETF Chart & Stats
$26.93
At close: 4:00 PM EST- Day’s Range
- $27.31 - $27.31
- 52-Week Range
- $19.21 - $29.64
- Previous Close
- $27.40
- Volume
- 20
- Average Volume (3M)
- 892
- AUM
- 24.74M
- NAV
- 27.18
- Expense Ratio
- 0.35%
- Holdings Count
- 50
- Beta
- 0.84
- Inception Date
- Sep 02, 2022
- Last Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
- Shares Outstanding
- 870,000
- Standard Deviation
- N/A
ETF Overview
VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD
The VanEck Genomics and Healthcare Innovators UCITS ETF Accum A USD, with ticker GB:CURE, is a cutting-edge investment vehicle designed for those seeking to capitalize on the transformative potential of the genomics and healthcare innovation sectors. This ETF strategically focuses on a sector that is at the forefront of scientific advancement, emphasizing a thematic niche that goes beyond traditional healthcare investments by targeting companies pioneering in genomics and related technologies. By investing in GB:CURE, investors gain exposure to a diversified portfolio of firms that are driving breakthroughs in genomic sequencing, genetic data analysis, and precision medicine, all of which hold the promise to revolutionize healthcare outcomes and efficiencies. The fund is meticulously curated to include companies that demonstrate robust innovation and growth potential, ensuring that investors are not just part of the healthcare story, but are positioned at its most innovative and disruptive frontier. As a sector-focused thematic ETF, GB:CURE offers a unique opportunity to align investment portfolios with future-forward healthcare solutions, catering to investors who are keen on participating in the long-term growth trajectory of genomics and healthcare innovation. This ETF serves as a gateway to the promising intersection of technology and healthcare, making it an appealing choice for those with a vision to invest in the next wave of medical advancement.
- Asset Class
- Equity
- Region
- Global
- Issuer
- VanEck
- Index Tracked
- MVIS Global Future Healthcare ESG Index - Benchmark TR Net
- Ticker Symbol
- GB:CURE
GB:CURE ETF News
Regeneron Updates Obesity Drug Study as Investors Await Results
Regeneron Pharmaceuticals ($REGN) announced an update on their ongoing clinical study. Study Overview: Regeneron Pharmaceuticals (NASDAQ: REGN) updated its Phase 2 study, officially titled “A Randomized, Double-Blind Study of The
1d agoREGN
GB:CURE ETF FAQ
What was GB:CURE’s price range in the past 12 months?
GB:CURE’s lowest price in the past 12 months was $19.21 and its highest was $29.64.
What is the AUM of GB:CURE?
As of Nov 12, 2026, the AUM of GB:CURE is $24.74M.
Is GB:CURE overvalued?
Based on Wall Street analyst price targets for GB:CURE’s holdings, GB:CURE’s price is currently undervalued.
How many shares outstanding does GB:CURE have?
GB:CURE has 870,000 shares outstanding.
GB:CURE ETF Smart Score
Top 10 Holdings
| Name | Weight % |
|---|---|
| MRNAModerna | 12.08% |
| REGNRegeneron Pharmaceuticals | 8.94% |
| VRTXVertex Pharmaceuticals Inc. | 7.90% |
| VEEVVeeva Systems Inc | 7.15% |
| NTRANatera Inc. | 5.47% |
| DXCMDexcom | 4.96% |
| ILMNIllumina | 4.89% |
| GHGuardant Health | 4.03% |
| BNTXBiontech Se Sponsored Adr | 3.38% |
| ALNYAlnylam Pharmaceuticals | 2.62% |
| Total | 61.42% |
